according to the Globally Harmonized System



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1.14 28.09.2024 564737-00015 Date of first issue: 15.03.2016

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Tafluprost Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road

Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (%	
		w/w)	
Tafluprost	209860-87-7	>= 0.0002 - < 0.0025	

4. FIRST AID MEASURES

according to the Globally Harmonized System



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1.14 28.09.2024 564737-00015 Date of first issue: 15.03.2016

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

None known.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms

delayed

and effects, both acute and

Protection of first-aiders Notes to physician No special precautions are necessary for first aid responders.

Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

parriers)

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

according to the Globally Harmonized System



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1.14 28.09.2024 564737-00015 Date of first issue: 15.03.2016

cannot be contained.

Methods and materials for containment and cleaning up Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling

Handle in accordance with good industrial hygiene and safety

practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage

Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Tafluprost	209860-87-7	TWA	0.002 μg/m3 (OEB 5)	Internal	
	Further information: Skin, Eye				
		Wipe limit	0.02 µg/100 cm ²	Internal	

Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to pre-

vent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems

are required.

according to the Globally Harmonized System



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1.14 28.09.2024 564737-00015 Date of first issue: 15.03.2016

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type and protection

Organic vapour type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Colour : clear

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

according to the Globally Harmonized System



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1.14 28.09.2024 564737-00015 Date of first issue: 15.03.2016

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower :

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

Can react with strong oxidizing agents.

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Incompatible materials : Oxidizing agent Hazardous decomposition : No hazardous decomposition

products

No hazardous decomposition products are known.

according to the Globally Harmonized System



Tafluprost Formulation

Revision Date: Date of last issue: 30.09.2023 Version SDS Number: 1.14 28.09.2024 564737-00015 Date of first issue: 15.03.2016

11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure Skin contact

Ingestion Eye contact

Inhalation

Acute toxicity

Not classified based on available information.

Components:

Tafluprost:

Acute oral toxicity LD50 (Rat): 665 mg/kg

LD50 (Rat): > 100 mg/kg

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of :

(Dog): 3 mg/kg

administration) Application Route: Intravenous

Target Organs: Cardio-vascular system

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Tafluprost:

Species Monkey

Result No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Tafluprost:

Test Type : Maximisation Test

Exposure routes : Dermal **Species** Guinea pig

Result Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

according to the Globally Harmonized System



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.14
 28.09.2024
 564737-00015
 Date of first issue: 15.03.2016

Components:

Tafluprost:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Tafluprost:

Species : Rat

Application Route : Subcutaneous Exposure time : 24 Months Result : negative

Species : Mouse

Application Route : Subcutaneous Exposure time : 18 Months Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Tafluprost:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Intravenous injection

Fertility: NOAEL: 100 µg/kg Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection Developmental Toxicity: LOAEL: 10 µg/kg

Result: Malformations were observed., Reduced foetal weight

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection Developmental Toxicity: NOAEL: 3 µg/kg

according to the Globally Harmonized System



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1.14 28.09.2024 564737-00015 Date of first issue: 15.03.2016

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous injection Developmental Toxicity: LOAEL: 0.03 µg/kg Result: Malformations were observed.

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 0.01 µg/kg

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection Developmental Toxicity: LOAEL: 1 µg/kg

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection Developmental Toxicity: NOAEL: 0.3 µg/kg

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

Components:

Tafluprost:

Target Organs : Lungs, Cardio-vascular system Assessment : Causes damage to organs.

STOT - repeated exposure

Not classified based on available information.

Components:

Tafluprost:

Target Organs : Lungs, Cardio-vascular system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Tafluprost:

Species : Rat

LOAEL : 0.01 mg/kg
Application Route : Intravenous
Exposure time : 6 Months

Target Organs : Cardio-vascular system, Blood, Bone marrow, Kidney, Liver,

according to the Globally Harmonized System



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1.14 28.09.2024 564737-00015 Date of first issue: 15.03.2016

spleen

Species : Dog

NOAEL : 0.0001 mg/kg
LOAEL : 0.001 mg/kg
Application Route : Intravenous
Exposure time : 39 Weeks

Target Organs : Cardio-vascular system, Eye

Symptoms : Dilatation of the pupil

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Tafluprost:

Eye contact : Symptoms: dryness of the eyes, Blurred vision

12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Tafluprost:

Partition coefficient: n-

octanol/water

log Pow: 4.5

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to the Globally Harmonized System



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 28.09.2024 564737-00015 Date of first issue: 15.03.2016 1.14

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS not determined

DSL not determined

IECSC not determined

16. OTHER INFORMATION

Revision Date 28.09.2024

Further information

Sources of key data used to compile the Safety Data

Sheet

Date format dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association: IBC - International Code for the Construction and

cy, http://echa.europa.eu/

Internal technical data, data from raw material SDSs, OECD

eChem Portal search results and European Chemicals Agen-

according to the Globally Harmonized System



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1.14 28.09.2024 564737-00015 Date of first issue: 15.03.2016

Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate: NOM - Official Mexican Norm: NTP - National Toxicology Program: NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods: vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN